{"created":"2023-05-15T15:02:35.297090+00:00","id":84863,"links":{},"metadata":{"_buckets":{"deposit":"782347e1-59a9-4269-a6ea-0ed6e4ed4d11"},"_deposit":{"created_by":1,"id":"84863","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"84863"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00084863","sets":["11"]},"author_link":["1023745","1023746"],"item_10004_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2021-10","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"10","bibliographicPageStart":"7","bibliographicVolumeNumber":"55","bibliographic_titles":[{"bibliographic_title":"臨床核医学"}]}]},"item_10004_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"悪性脳腫瘍は既存治療法では多くが再発し、新治療法の開発が必要な希少難治がんである。これまでに、既存の治療法が奏功しない原因として、腫瘍の内部が低酸素化し、治療抵抗性になることが知られている。これに対し我々は、再発悪性脳腫瘍に対し革新的治療法を提供すべく、低酸素化をきたした腫瘍に高集積し、高い治療効果を発揮する放射性治療薬64Cu-ATSMを開発し、第I相試験を行っている。本臨床試験は、国産の放射性治療薬を用いた国内初の治験となり、臨床医からの期待も高い。本稿では、本臨床試験に至るまでの開発経緯を概説するとともに、その経験から得た放射性薬剤開発に必要なプロセスにつきまとめたい。","subitem_description_type":"Abstract"}]},"item_10004_relation_17":{"attribute_name":"関連サイト","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://www.rinshokaku.com/magazines/2022/55_1.pdf","subitem_relation_type_select":"URI"}}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"吉井, 幸恵"}],"nameIdentifiers":[{"nameIdentifier":"1023745","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Yukie, Yoshii","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"1023746","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"日本発放射性治療薬64Cu-ATSMによる再発悪性脳腫瘍に対する革新的治療法の開発―その経験から","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"日本発放射性治療薬64Cu-ATSMによる再発悪性脳腫瘍に対する革新的治療法の開発―その経験から"}]},"item_type_id":"10004","owner":"1","path":["11"],"pubdate":{"attribute_name":"公開日","attribute_value":"2021-10-26"},"publish_date":"2021-10-26","publish_status":"0","recid":"84863","relation_version_is_last":true,"title":["日本発放射性治療薬64Cu-ATSMによる再発悪性脳腫瘍に対する革新的治療法の開発―その経験から"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T18:08:40.261098+00:00"}